Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01177397 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
A Phase 1 study of Non-Small Cell Lung Cancer and Multiple Myeloma, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 226
- Enrollment target
- 16
- Study locations
NCT01177397 is a Phase 1 study of Non-Small Cell Lung Cancer and Multiple Myeloma that has completed, run by Celgene. The registered enrollment target is 226 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (66% lower). The trial reports 16 study locations across 9 states.
The verdict
NCT01177397, a Phase 1 study of Non-Small Cell Lung Cancer and Multiple Myeloma, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 226 participants
- Enrollment target
- 16
- Study locations
Study Summary
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to determine the appropriate dose and tumor type for later-stage clinical trials.
Conditions Studied
Interventions
- DRUG CC-223
Study Locations (16)
Other
- Institut Claudius Regaud - Toulouse
- Institut Gustave Roussy Faculte de Medecine Paris Sud Service de pneumologie - Villejuif
- Hospital Universitario de Salamanca - Salamanca
- Hospital Universitario Virgen Del Rocio - Seville
- Sarah Cannon Research Institute UK - London
- UCL Cancer Institute - London
California
- Cedars-Sinai Medical Center - Los Angeles
- UCLA Neuro-Oncology Program - Los Angeles
- University of California, San Francisco Hellen Diller Family Comprehensive Cancer Center - San Francisco
Florida
- Moffitt Cancer Center - Tampa
Minnesota
- Mayo Clinic Cancer Clinical Studies Unit - Rochester
Montana
- Billings Clinic - Billings
New Jersey
- Hackensack University Medical Center - Hackensack
New York
- NYU Cancer Institute - Bellevue Hospital - New York
Tennessee
- Sarah Cannon Research Institute Drug Development Unit - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2010-07-20 |
| Est. Completion | 2016-12-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01177397
The ClinicalTrials.gov registry entry for NCT01177397 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (66% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which CC-223 is the first listed.
NCT01177397 reports 16 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01177397 about?
NCT01177397 is a clinical study titled "Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma". The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to determine the appropriate dose and tumor type for later-stage clinical trial...
What is the current status of trial NCT01177397?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 226 participants. The study started on 2010-07-20. Estimated completion is 2016-12-09.
What conditions does trial NCT01177397 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Multiple Myeloma, Hepatocellular Carcinoma, Diffuse Large B Cell Lymphoma, Glioblastoma Multiforme.
What interventions are being tested in trial NCT01177397?
The interventions under investigation include: CC-223 (DRUG).
Who is sponsoring clinical trial NCT01177397?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01177397 being conducted?
This trial has 16 study locations across California, Florida, Minnesota, Montana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.